PRKAA1 and metabolic disease: CRISPR/Cas9‐mediated targeted editing of AMPK subunits has elucidated its pivotal role in regulating metabolic disorders, while demonstrating that intact AMPK functionality is essential for the antitumor effects of pharmacological activators.